Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 1998

View Archived Issues

Company Profile: Amrad

PPL Therapeutics: year-end 1997 highlights

Chiroscience: year-end 1997 highlights

Spotlight on AIDS vaccines

Alprox-TD efficacy established in Argentinian clinical trial

Novel isoquinolines prepared at Snow Brand Milk Products inhibit neuronal cell death

Antifungal agents disclosed by Nippon Soda

Senetek's ED treatment shows 83% response rate

Matrigen and Prizm merge to form Selective Genetics

Photogen Technologies receives grant from NIH

Vitrase shown to clear vitreous hemorrhage

Sparta completes patient treatment phase in Spartaject busulfan trial

Perkin-Elmer and the Institute for Genomic Research form new genomics company

Anergen receives SBIR grant for diabetes treatment development

Corvas' small-protein antithrombotic enters U.S. clinical trials

Verteporfin proven safe in phase III trials

Abbott introduces new drug for hyperparathyroidism in U.S.

Aviron's FluMist influenza vaccine is effective in children

Andaris granted U.S. patent for microcapsule technology

PolyHeme to undergo European phase III trials

FDA advisory committee denies recommendation for Ergoset

Scriptgen and Boston University synthesize new antibiotics

Neurogen: Q1 1998 highlights

Eisai selects new triazole antifungal for further development

Clinical efficacy and safety of sildenafil in men with ED

Pharmacological profile of lafutidine and related compounds

Antigenics receives patent protection for HSP-based cancer immunotherapy

FDA requests more information for Osteopatch 510(k) approval

Sanofi receives expanded approval for oxaliplatin in France

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 10, 2026